Harbor
Claim my $200
SemaglutideMarch 13, 2026

Semaglutide Cost in 2026: Ozempic, Wegovy Injection, and the New Wegovy Pill Compared

Semaglutide Cost in 2026: Ozempic, Wegovy Injection, and the New Wegovy Pill Compared

If you've tried to pin down what semaglutide actually costs in 2026, you already know the answer depends on which brand you're taking and whether your insurer decided this was the year to start covering weight management. The pricing landscape has shifted dramatically since Novo Nordisk launched the oral Wegovy pill in January 2026, slashed self-pay prices through a White House deal, and announced a 50% list price reduction coming in 2027. Ozempic, Wegovy injection, and the new Wegovy pill each have different list prices and savings programs. What you'll actually pay ranges from $0 per month to well over $1,300, and understanding why requires a closer look at each option, each payer channel, and the policy shifts reshaping access this year.

Three Brands, Two Delivery Methods: A Quick Orientation

It helps to understand the product landscape before diving into costs. The differences and similarities between various semaglutide delivery methods, specifically with the traditional injection forms of Ozempic and Wegovy, and the newly introduced Wegovy pill. All three medications contain the same active ingredient, semaglutide, but they serve different approved uses and come in different forms.

  • Ozempic is a once-weekly injectable pen approved for the management of type 2 diabetes. It is not FDA-approved for weight loss, though physicians widely prescribe it off-label for that purpose. It comes in four dose strengths: 0.25 mg, 0.5 mg, 1 mg, and 2 mg.
  • Wegovy injection is a once-weekly injectable pen approved specifically for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition. It was also the first GLP-1 medication approved to reduce cardiovascular risk.
  • Wegovy pill is the newest addition, FDA-approved in December 2025 and broadly available across U.S. pharmacies since January 2026. It's a once-daily oral tablet — the first and only oral GLP-1 approved for weight loss in adults. A 64-week study of 307 adults, the pill produced an average weight loss of 16.6% of body weight among completers, with one in three participants losing 20% or more. That puts it roughly on par with injectable Wegovy's efficacy, though the pill requires daily dosing rather than weekly.

The pill's approval changed the conversation about access. For the millions of patients who avoided GLP-1 treatment because of needle aversion, the oral option removes a significant barrier, and it launched with notably aggressive pricing.

Semaglutide for weight loss results shown as a slender woman in a white crop top pulls out the wide waistband of her oversized distressed denim jeans against a light gray background

What Semaglutide Actually Costs

essential details that consumers may need to know regarding the accessibility, insurance coverage, and general availability of semaglutide products as their pricing changes.

The Self-Pay Channel

Novo Nordisk overhauled its self-pay pricing strategy in early 2026, driven partly by a drug-pricing agreement with the White House and partly by competitive pressure from compounding pharmacies offering cut-rate semaglutide alternatives of questionable safety. Self-pay patients now have access to tiered pricing across all three products:

  • Wegovy pill (1.5 mg and 4 mg starting doses): $149 per month for new patients. After April 15, 2026, the 4 mg dose rises to $199 per month. The maintenance doses of 9 mg and 25 mg cost $299 per month.
  • Wegovy injection and Ozempic (0.25 mg, 0.5 mg, 1 mg): $199 per month introductory price for new self-pay patients through March 31, 2026 — good for the first two months of therapy. After the introductory period, the standard self-pay price is $349 per month.
  • Ozempic 2 mg: $499 per month, with no introductory discount on this dose.

These are cash prices available without insurance, delivered directly through NovoCare Pharmacy or participating telehealth platforms and retail pharmacies, including CVS and Costco. They represent steep markdowns from the list price, roughly 74% off the Wegovy pill's starting dose and 74% off the Wegovy injection's introductory price.

GoodRx and Third-Party Discount Pricing

Discount platforms have also responded to the new pricing structure. GoodRx announced pricing that matches or undercuts some of Novo Nordisk's direct offers. Through April 15, 2026, GoodRx lists the 1.5 mg and 4 mg oral semaglutide doses at $149 per month. After that date, the 4 mg dose moves to $199. Higher oral doses (9 mg and 25 mg) are priced at $299 through GoodRx. For injectable Ozempic, GoodRx advertises prices as low as $199.

Where Telehealth Providers Fit In

Platforms like Harbor offer physician-guided weight management programs that pair licensed U.S. physician evaluations with compounded GLP-1 medications shipped directly to patients' doors. Harbor's program, which features compounded semaglutide injections, runs $132 per month and includes physician access, dietitian support, and a treatment plan designed around program completion rather than indefinite medication use. For patients who want support beyond just filling a prescription, nutritional guidance, physician oversight, and structured treatment planning, these telehealth platforms bridge the gap between pharmacy-only self-pay and full clinical programs, without requiring insurance.

Commercial Insurance: Coverage Is Expanding, But Gatekeeping Persists

Coverage Rates by Employer Size

Coverage correlates strongly with company size. According to recent employer survey data, 43% of very large employers (5,000+ employees) now cover GLP-1 medications for weight loss. That figure drops to 30% for large employers (1,000–4,999 employees) and just 16% for mid-size employers (200–999 workers). If you work for a smaller company, the odds are stacked against you.

Among patients with commercial coverage, Novo Nordisk reports that 90% of covered patients pay between $0 and $25 per month through the company's savings card programs. For Ozempic specifically, the copay savings card brings the cost to as little as $25 per month for eligible commercially insured patients. Wegovy's savings program can reduce the cost to $0 for qualifying patients.

The PBM Puzzle

Your experience depends heavily on which PBM manages your plan's formulary.

  • CVS Caremark (administering Aetna plans): Since July 2025, Wegovy has been the preferred GLP-1 on CVS Caremark formularies. Coverage typically requires prior authorization, but the preferred status means lower-tier placement and better copay structures.
  • Express Scripts (administering Cigna plans): The standard Express Scripts formulary does not include weight-loss medications. However, the Evernorth cost-cap program is expanding to more employer plans throughout 2026.
  • OptumRx (administering UnitedHealthcare plans): UnitedHealthcare commercial plans using OptumRx often cover Wegovy for weight loss with prior authorization. Coverage for the new oral form is expected to follow similar authorization requirements as the injectable version.

Even with coverage, most commercial plans require prior authorization for semaglutide, which is a process that can take days to weeks and frequently results in initial denials. Common requirements include documented BMI thresholds, evidence of failed lifestyle interventions, and sometimes step therapy requiring patients to try older, cheaper weight-loss medications first. The prior authorization burden is real, and patients should be prepared to work closely with their prescribing physician to navigate the appeals process if an initial request is denied.

Medicare Part D: Limited Access With Major Caveats

Medicare Part D does not cover semaglutide prescribed solely for weight loss. The law has historically excluded anti-obesity medications from Part D coverage, and despite bipartisan legislative attempts to change this, that exclusion remains broadly intact as of March 2026. Because Wegovy received FDA approval to reduce cardiovascular risk in adults with established cardiovascular disease who are overweight or obese, Medicare Part D plans can cover Wegovy when prescribed for that cardiovascular indication. If your physician prescribes Wegovy specifically for cardiovascular risk reduction, and your Part D plan includes it on its formulary, you may qualify for coverage. It requires documented cardiovascular disease plus a BMI above 27. A physician cannot simply prescribe Wegovy for weight management and bill it under the cardiovascular indication. There needs to be a legitimate clinical basis.

Semaglutide injection self-administered by a person in a white ribbed top pressing a blue and white auto-injector pen into their bare abdomen with visible stretch marks

The 2026 Out-of-Pocket Cap

For Medicare beneficiaries who do qualify for Wegovy coverage under the cardiovascular indication, 2026 brings some financial relief. Part D now caps total yearly out-of-pocket drug costs at $2,000. Plans can also carry a deductible of up to $590. So even if you're paying a percentage of the drug cost rather than a flat copay, your annual exposure is capped.

Pilot Programs and the BALANCE Model

The Centers for Medicare and Medicaid Services (CMS) launched the BALANCE model in December 2025. State programs and manufacturers were asked to submit participation intentions by January 8, 2026, with the model expected to launch in May 2026. While this doesn't directly affect Medicare, it signals a policy direction that could eventually influence Part D coverage decisions.

Medicaid: A Patchwork of State-by-State Decisions

As of January 2026, only 13 state Medicaid programs cover GLP-1 medications for obesity treatment under fee-for-service. That number has actually decreased recently, as four states, California, New Hampshire, Pennsylvania, and South Carolina, eliminated GLP-1 obesity coverage, citing budget pressures and the significant costs associated with expanding access.

States are pulling back because the math is daunting for state budget offices. With an estimated 42% of American adults meeting clinical criteria for obesity, unrestricted Medicaid coverage of GLP-1 medications would represent an enormous fiscal commitment. States are weighing clinical benefits against budget realities, and in 2026, the budget side is winning in most legislatures. A few states are actively considering further restrictions on obesity drug coverage for the fiscal years 2026 and 2027. Enthusiasm for expanding obesity drug access has cooled, with cost remaining the dominant factor in coverage decisions.

The 2027 List Price Reset: What It Means

Who Benefits

There are anticipated reductions in the cost of semaglutide medications, such as Ozempic and Wegovy, in future years, including 2026 and 2027. List price reductions primarily affect the insured channel. Specifically, patients whose copay or coinsurance is calculated as a percentage of the drug's list price, and payers negotiating for formulary placement. For commercially insured patients already paying $0 to $25 through savings programs, the list price cut may not change their out-of-pocket cost at all. For Medicare Part D beneficiaries who qualify for Wegovy's cardiovascular indication, the lower list price could meaningfully reduce coinsurance obligations and help more patients stay within the $2,000 annual out-of-pocket cap.

Finding Your Lowest Price: A Decision Framework

With so many variables, finding the best price requires a methodical approach. Here's how to think through it:

  1. If you have commercial insurance with GLP-1 coverage, check whether Wegovy (injectable or pill) is on your plan's formulary. If it is, apply for the Novo Nordisk savings card. You may pay $0 to $25 per month. For Ozempic, the savings card can bring costs to $25 per month for covered patients.
  2. If you have commercial insurance without weight-loss drug coverage, you're functionally a self-pay patient. The NovoCare Pharmacy route offers $149 per month for oral Wegovy starter doses, or introductory pricing of $199 per month for Wegovy injection and Ozempic. GoodRx may match or beat these prices on certain doses.
  3. If you're on Medicare Part D, coverage is only available if your physician prescribes Wegovy for cardiovascular risk reduction (not weight loss) and your specific plan includes it on its formulary. If you qualify, the $2,000 annual out-of-pocket cap provides a financial ceiling.
  4. If you're on Medicaid, check whether your state is among the 13 that cover GLP-1s for obesity. If not, self-pay through NovoCare or a provider like Harbor may be the most accessible path. Harbor's structured telehealth programs start at $132 per month for physician-guided semaglutide treatment and include clinical support that Medicaid patients might otherwise lack.
  5. If you prefer the pill over injections, oral Wegovy is the only GLP-1 pill approved for weight loss. Starting doses run $149 per month self-pay, scaling to $299 per month at maintenance doses. The pill is not yet widely covered by insurance formularies, but coverage is expected to expand throughout 2026 as PBMs update their drug lists.

The semaglutide pricing landscape is moving faster than at any point since these drugs first launched.

Semaglutide treatment progress tracked as a person steps barefoot onto a white digital body weight scale on a light tile floor

The best strategy is an informed one. Know your insurance formulary, use manufacturer savings programs aggressively, compare pricing across NovoCare, GoodRx, and telehealth platforms, and have a candid conversation with your prescriber about which product and dose make sense for both your health and your budget.

Sources: